FR21C1063I1 - COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS - Google Patents

COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS

Info

Publication number
FR21C1063I1
FR21C1063I1 FR21C1063C FR21C1063C FR21C1063I1 FR 21C1063 I1 FR21C1063 I1 FR 21C1063I1 FR 21C1063 C FR21C1063 C FR 21C1063C FR 21C1063 C FR21C1063 C FR 21C1063C FR 21C1063 I1 FR21C1063 I1 FR 21C1063I1
Authority
FR
France
Prior art keywords
combination treatment
expressing tumors
tumors
expressing
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1063C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1063(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genmab AS filed Critical Genmab AS
Publication of FR21C1063I1 publication Critical patent/FR21C1063I1/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
FR21C1063C 2006-09-26 2021-12-20 COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS Active FR21C1063I1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84732906P 2006-09-26 2006-09-26
DKPA200601232 2006-09-26
PCT/DK2007/000418 WO2008037257A2 (en) 2006-09-26 2007-09-26 Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors

Publications (1)

Publication Number Publication Date
FR21C1063I1 true FR21C1063I1 (en) 2022-02-18

Family

ID=39156080

Family Applications (6)

Application Number Title Priority Date Filing Date
FR19C1055C Active FR19C1055I1 (en) 2006-09-26 2019-10-09 COMBINED TREATMENT OF TUMORS EXPRESSING CD38
FR19C1056C Active FR19C1056I1 (en) 2006-09-26 2019-10-09 COMBINED TREATMENT OF TUMORS EXPRESSING CD38
FR19C1057C Active FR19C1057I1 (en) 2006-09-26 2019-10-09 COMBINED TREATMENT OF TUMORS EXPRESSING CD38
FR20C1034C Active FR20C1034I1 (en) 2006-09-26 2020-07-16 COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS
FR21C1063C Active FR21C1063I1 (en) 2006-09-26 2021-12-20 COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS
FR21C1062C Active FR21C1062I1 (en) 2006-09-26 2021-12-20 COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS

Family Applications Before (4)

Application Number Title Priority Date Filing Date
FR19C1055C Active FR19C1055I1 (en) 2006-09-26 2019-10-09 COMBINED TREATMENT OF TUMORS EXPRESSING CD38
FR19C1056C Active FR19C1056I1 (en) 2006-09-26 2019-10-09 COMBINED TREATMENT OF TUMORS EXPRESSING CD38
FR19C1057C Active FR19C1057I1 (en) 2006-09-26 2019-10-09 COMBINED TREATMENT OF TUMORS EXPRESSING CD38
FR20C1034C Active FR20C1034I1 (en) 2006-09-26 2020-07-16 COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR21C1062C Active FR21C1062I1 (en) 2006-09-26 2021-12-20 COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS

Country Status (23)

Country Link
US (4) US9040050B2 (en)
EP (3) EP3569245A1 (en)
JP (6) JP5476122B2 (en)
AU (2) AU2007302448C1 (en)
CA (1) CA2664740C (en)
CY (7) CY1121813T1 (en)
DK (1) DK2081595T3 (en)
EA (1) EA034877B1 (en)
ES (1) ES2732278T3 (en)
FR (6) FR19C1055I1 (en)
HR (1) HRP20191115T1 (en)
HU (6) HUE044136T2 (en)
IL (2) IL197727A (en)
LT (7) LT2081595T (en)
LU (3) LUC00129I2 (en)
ME (1) ME03503B (en)
NZ (1) NZ576122A (en)
PL (1) PL2081595T3 (en)
PT (1) PT2081595T (en)
RS (1) RS59005B1 (en)
SI (1) SI2081595T1 (en)
TR (1) TR201910145T4 (en)
WO (1) WO2008037257A2 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107033243B (en) * 2005-03-23 2020-12-15 根马布股份公司 CD38 antibodies for the treatment of multiple myeloma
PL2081595T3 (en) * 2006-09-26 2019-11-29 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP2191841A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
MX2012004406A (en) * 2009-10-21 2012-05-08 Immunogen Inc Novel dosing regimen and method of treatment.
JP6093696B2 (en) 2010-06-09 2017-03-08 ゲンマブ エー／エス Antibody against human CD38
ES2617446T3 (en) * 2010-09-27 2017-06-19 Morphosys Ag Anti-cd38 and lenalidomide or bortezomib antibody for the treatment of multiple myeloma and nhl
UA112170C2 (en) * 2010-12-10 2016-08-10 Санофі ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB
JOP20210044A1 (en) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
US9427477B2 (en) 2011-05-09 2016-08-30 Mayo Foundation For Medical Education And Research Cancer treatments
SG11201401518TA (en) 2011-10-28 2014-05-29 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
PT2900232T (en) 2012-09-25 2018-02-09 Morphosys Ag Combinations and uses thereof
WO2014055415A1 (en) 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (en) * 2012-12-07 2018-12-26 Санофі Compositions comprising anti-cd38 antibodies and lenalidomide
IL241407B (en) * 2013-03-13 2022-06-01 Univ California Compositions comprising anti-cd38 antibodies and carfilzomib
PT2992013T (en) 2013-04-29 2020-03-05 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
JP2016536314A (en) * 2013-10-31 2016-11-24 サノフイ Specific anti-CD38 antibodies for treating human cancer
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) * 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
UA119352C2 (en) * 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof
US10213513B2 (en) * 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
US10617757B2 (en) * 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
WO2016040294A2 (en) * 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
CA2965414C (en) 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
NZ732753A (en) * 2014-12-04 2024-08-30 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemia
HUE054271T2 (en) 2015-05-13 2021-08-30 Morphosys Ag Treatment for multiple myeloma (mm)
KR102602754B1 (en) * 2015-05-20 2023-11-14 얀센 바이오테크 인코포레이티드 Anti-CD38 antibodies for treating light chain amyloidosis and other CD38-positive hematological malignancies
ES2890783T3 (en) 2015-06-22 2022-01-24 Janssen Biotech Inc Combination therapies for hematologic malignancies with anti-CD38 antibodies and survivin inhibitors
FI3313441T3 (en) * 2015-06-24 2024-03-28 Janssen Biotech Inc Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
US20170044265A1 (en) * 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
TW201707725A (en) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 Carrier-antibody compositions and methods of making and using the same
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN108472369A (en) 2015-11-03 2018-08-31 詹森生物科技公司 The subcutaneous preparations and application thereof of 8 antibody of AntiCD3 McAb
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
AU2017217881B2 (en) 2016-02-12 2022-11-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
US11878061B2 (en) 2016-03-21 2024-01-23 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
WO2017165440A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
JP2019526579A (en) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Methods and compositions for targeting T cell cancer
EP3506942B1 (en) 2016-09-01 2022-11-16 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
EP3510048A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Methods of treating pd-l1 expressing cancer
CN109890422A (en) 2016-09-06 2019-06-14 梅约医学教育与研究基金会 Taxol-albumin-binding agent composition and the method for using and preparing the composition
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
US11337975B2 (en) 2016-11-23 2022-05-24 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereof
CN110248669B (en) 2016-12-09 2023-09-08 昂克医疗有限公司 Engineered natural killer cells and uses thereof
BR112020002636A2 (en) * 2017-08-10 2020-07-28 Grifols Diagnostic Solutions Inc. compositions, methods and / or kits comprising a recombinant extracellular domain of human cd38
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
MA50514A (en) 2017-10-31 2020-09-09 Janssen Biotech Inc HIGH-RISK MULTIPLE MYELOMA TREATMENT METHODS
JP6648171B2 (en) * 2018-02-02 2020-02-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド Fusion with anti-CD38 antibody and attenuated interferon alpha-2B
BR112020023187A2 (en) * 2018-05-16 2021-04-20 Janssen Biotech, Inc. methods for treating cancers and increasing the effectiveness of therapeutic t-cell redirecting agents
TW202019518A (en) 2018-07-13 2020-06-01 丹麥商珍美寶股份有限公司 Variants of cd38 antibody and uses thereof
US20240254252A1 (en) 2018-07-13 2024-08-01 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
WO2020072840A1 (en) * 2018-10-03 2020-04-09 Prescient Pharma Llc Compositions and methods for isolating circulating cells
KR20220002891A (en) 2019-03-15 2022-01-07 모르포시스 아게 Anti-CD38 antibody and pharmaceutical composition thereof for treatment of autoantibody-mediated autoimmune disease
AR120054A1 (en) 2019-06-10 2022-02-02 Takeda Pharmaceuticals Co POLYTHERAPIES WITH CD-38 ANTIBODIES
GB201916150D0 (en) 2019-11-06 2019-12-18 Univ Of Ireland Galway Treatment of multiple myeloma
CN112876563B (en) 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 Pharmaceutical composition, preparation method and application thereof
JP6853392B2 (en) * 2020-01-15 2021-03-31 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド Fusion with anti-CD38 antibody and attenuated interferon alfa-2B
WO2021144457A1 (en) 2020-01-16 2021-07-22 Genmab A/S Formulations of cd38 antibodies and uses thereof
CA3173257A1 (en) 2020-02-26 2021-09-02 Biograph 55, Inc. C19 c38 bispecific antibodies
US11684676B2 (en) 2020-05-08 2023-06-27 University Of Southern California Site-specific antibody-drug conjugates by ADP-ribosyl cyclases
KR20230079074A (en) * 2020-09-01 2023-06-05 더 리전츠 오브 더 유니버시티 오브 캘리포니아 Immunoglobulin E antibody compositions and methods of use
WO2022152823A1 (en) 2021-01-14 2022-07-21 Morphosys Ag Anti-cd38 antibodies and their uses
TW202302642A (en) 2021-03-01 2023-01-16 德商莫菲西斯公司 Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection
TW202321303A (en) 2021-07-19 2023-06-01 德商莫菲西斯公司 Treatment of anti-pla2r-autoantibody-mediated membranous nephropathy
WO2024094660A1 (en) 2022-10-31 2024-05-10 Genmab A/S Cd38 antibodies and uses thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1989008114A1 (en) 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992001049A2 (en) 1990-07-13 1992-01-23 The General Hospital Corporation Cd53 cell surface antigen and use thereof
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (en) 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
DK0564531T3 (en) 1990-12-03 1998-09-28 Genentech Inc Enrichment procedure for variant proteins with altered binding properties
ATE363532T1 (en) 1991-03-01 2007-06-15 Dyax Corp METHOD FOR PRODUCING BINDING MINIPROTEINS
ES2315612T3 (en) 1991-04-10 2009-04-01 The Scripps Research Institute GENOTECAS OF HETERODYMERIC RECEPTORS USING PHAGEMIDS.
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
WO1993001227A1 (en) 1991-07-08 1993-01-21 University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JPH05244982A (en) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd Humanized b-b10
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
WO1994017184A1 (en) 1993-01-29 1994-08-04 Schering Corporation Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
JP3801196B2 (en) 1993-03-09 2006-07-26 ジェンザイム・コーポレイション Isolation of the target compound from milk
JPH08509612A (en) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド Transgenic non-human animal capable of producing heterologous antibody
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
JP4233608B2 (en) 1996-10-15 2009-03-04 塩野義製薬株式会社 Autoantibody measurement method
WO1998016254A1 (en) 1996-10-17 1998-04-23 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
WO2000006194A2 (en) 1997-02-05 2000-02-10 Biotransplant, Inc. Depletion of cells responsible for antibody-mediated graft rejection
EP0975674B1 (en) 1997-05-02 2005-08-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Immunotoxins, comprising an onc protein, directed against malignant cells
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6719977B1 (en) 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
JP2002509716A (en) 1998-03-31 2002-04-02 ユニバーシティ テクノロジー コーポレイション Methods and compositions for raising an immune response to a telomerase antigen
CA2329940A1 (en) * 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
ATE414536T1 (en) * 1998-08-11 2008-12-15 Biogen Idec Inc COMBINATION THERAPIES AGAINST B-CELL LYMPHOMAS INCLUDING THE ADMINISTRATION OF ANTI-CD20 ANTIBODIES
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
US20050037969A1 (en) * 1999-05-14 2005-02-17 Arbor Vita Corporation Molecular interactions in hematopoietic cells
DE60037896D1 (en) 1999-07-29 2008-03-13 Medarex Inc HUMAN ANTIBODIES AGAINST HER2 / NEU
EP3214175A1 (en) 1999-08-24 2017-09-06 E. R. Squibb & Sons, L.L.C. Human ctla-4 antibodies and their uses
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
AU1331802A (en) 2000-10-17 2002-04-29 Trudeau Inst Inc Cd38 modulated chemotaxis
US20070042436A1 (en) 2000-10-17 2007-02-22 Lund Frances E CD38 modulated chemotaxis
AU2002235141A1 (en) 2000-11-27 2002-06-03 Geron Corporation Glycosyltransferase vectors for treating cancer
PT1354034E (en) 2000-11-30 2008-02-28 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CN1966525A (en) 2001-06-13 2007-05-23 根马布股份公司 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US20040166490A1 (en) 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20040019915A1 (en) * 2002-04-01 2004-01-29 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
EP1393720A1 (en) 2002-08-27 2004-03-03 Universiteit Utrecht Vesicle-encapsulated corticosteroids for treatment of cancer
MXPA05004022A (en) * 2002-10-17 2005-10-05 Genmab As Human monoclonal antibodies against cd20.
WO2004045512A2 (en) 2002-11-15 2004-06-03 Genmab A/S Human monoclonal antibodies against cd25
AU2003299641C1 (en) 2002-12-16 2016-06-02 Cormorant Pharmaceuticals Ab Human monoclonal antibodies against interleukin 8 (IL-8)
CA2534639C (en) * 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
CA2542840A1 (en) 2003-10-22 2005-05-12 University Of Rochester Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis
WO2005044855A2 (en) * 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
OA13284A (en) * 2003-11-06 2007-01-31 Corporation Celgene Methods and compositions using thalidomide for thetreatment and management of cancers and other dis eases.
SI2511297T1 (en) * 2004-02-06 2015-07-31 Morphosys Ag Anti-CD38 human antibodies and uses therefor
ES2541489T3 (en) 2004-02-06 2015-07-21 Morphosys Ag Human anti-CD38 antibodies and uses for them
US20050266008A1 (en) * 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies
KR20070004081A (en) * 2004-04-21 2007-01-05 다이니폰 인사츠 가부시키가이샤 Color filter and liquid crystal display device using the same
US20060019303A1 (en) * 2004-07-23 2006-01-26 Boehringer Ingelheim Pharmaceuticals, Inc. Method to identify and analyze genes having modified expression in stimulated T cells
CN107033243B (en) * 2005-03-23 2020-12-15 根马布股份公司 CD38 antibodies for the treatment of multiple myeloma
US20090123950A1 (en) 2005-05-24 2009-05-14 Morphosys Ag Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38
PL2081595T3 (en) * 2006-09-26 2019-11-29 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma

Also Published As

Publication number Publication date
CA2664740A1 (en) 2008-04-03
AU2007302448A1 (en) 2008-04-03
HUS2100057I1 (en) 2022-01-28
AU2013203186A1 (en) 2013-05-02
FR19C1057I1 (en) 2019-11-15
ES2732278T3 (en) 2019-11-21
ME03503B (en) 2020-04-20
HUS2100056I1 (en) 2022-01-28
CY1121813T1 (en) 2020-05-29
FR19C1055I1 (en) 2019-11-15
AU2013203186B2 (en) 2016-06-16
JP2010504363A (en) 2010-02-12
HUS1900045I1 (en) 2019-11-28
SI2081595T1 (en) 2019-10-30
CA2664740C (en) 2021-11-16
US20200114000A1 (en) 2020-04-16
US9040050B2 (en) 2015-05-26
US20100092489A1 (en) 2010-04-15
LTPA2019515I1 (en) 2019-10-25
LUC00128I2 (en) 2024-05-22
AU2013203186C1 (en) 2019-02-14
HUE044136T2 (en) 2019-09-30
LTPA2021015I1 (en) 2022-01-25
CY2021038I1 (en) 2022-03-24
JP6907165B2 (en) 2021-07-21
EP3569245A1 (en) 2019-11-20
LUC00130I2 (en) 2024-05-22
TR201910145T4 (en) 2019-08-21
HUS1900043I1 (en) 2019-11-28
NZ576122A (en) 2012-09-28
JP2016188228A (en) 2016-11-04
AU2007302448B2 (en) 2013-12-19
EA200970317A1 (en) 2009-10-30
CY2021038I2 (en) 2023-11-15
IL197727A0 (en) 2011-08-01
LTPA2020520I1 (en) 2020-07-27
LTPA2021014I1 (en) 2022-01-10
LTPA2019514I1 (en) 2019-10-25
IL248204A0 (en) 2016-11-30
JP5476122B2 (en) 2014-04-23
JP2019001804A (en) 2019-01-10
JP6607825B2 (en) 2019-11-20
JP2021119198A (en) 2021-08-12
CY2019036I1 (en) 2020-05-29
EP2081595A2 (en) 2009-07-29
PT2081595T (en) 2019-07-16
FR20C1034I1 (en) 2020-10-02
US20240165226A1 (en) 2024-05-23
CY2019036I2 (en) 2020-05-29
CY2019037I1 (en) 2020-05-29
CY2020016I1 (en) 2020-11-25
PL2081595T3 (en) 2019-11-29
JP2014141492A (en) 2014-08-07
JP2023120436A (en) 2023-08-29
CY2019037I2 (en) 2020-05-29
FR21C1062I1 (en) 2022-02-18
EP3753576A1 (en) 2020-12-23
IL197727A (en) 2017-01-31
DK2081595T3 (en) 2019-07-15
WO2008037257A3 (en) 2008-06-05
CY2020016I2 (en) 2020-11-25
HRP20191115T1 (en) 2019-09-20
EP2081595B1 (en) 2019-04-10
CY2019035I1 (en) 2020-05-29
CY2021037I2 (en) 2022-03-24
HUS1900044I1 (en) 2019-11-28
LT2081595T (en) 2019-07-10
RS59005B1 (en) 2019-08-30
FR19C1056I1 (en) 2019-11-15
LTPA2019516I1 (en) 2019-10-25
CY2021037I1 (en) 2022-03-24
EA034877B1 (en) 2020-04-01
CY2019035I2 (en) 2020-05-29
US20150231235A1 (en) 2015-08-20
LUC00129I2 (en) 2024-05-22
AU2007302448C1 (en) 2019-02-14
WO2008037257A2 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
FR21C1062I1 (en) COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS
BRPI0821779A2 (en) therapeutic treatment of cancer
BRPI0821660A2 (en) Combinations of therapeutic agents for cancer treatment
BRPI0811265A2 (en) TREATMENT OF SYNUCLEINOPATHIES
BRPI0908026A2 (en) Methods for the treatment of bowel diseases
BRPI0921482A2 (en) treatment of acute lymphoblastic leukemia
EP2049139A4 (en) Treatment of ras-expressing tumors
BRPI0814624A2 (en) TREATMENT OF PROGRESIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST
SMAP200900085A (en) 3-imidazolyl-indoles for the treatment of malolysiseproliferative
BRPI0912683A2 (en) treatment of metastatic tumors
ATE434620T1 (en) DIHYDROTHIENOPYRIMIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES
IL197315A0 (en) Treatment of cancer
DK2056842T3 (en) Modified galactosylceramide for the treatment of cancerous diseases
DE602007006594D1 (en) Endoscope treatment instrument
BRPI0815551A2 (en) TREATMENT THROUGH HUCBC OF BETA-AMYLOID DISEASE
FR2901405B1 (en) TREATMENT APPARATUS
BRPI0922884A2 (en) cancer treatment compounds
BRPI0715728A2 (en) treatment of cartilaginous disorder
MA28901B1 (en) METHOD OF TREATING CANCERS
GB0700972D0 (en) Treatment of inflammatory disease
LTC2066352I2 (en) Treatment of Multiple Sclerosis (MS) with Campan-1H
FI20095600A (en) Composition for the treatment of skin diseases
FR2884647B1 (en) TREATMENT OF SEMICONDUCTOR PLATES
FR2897533B1 (en) OXIDIZING AGENT FOR THE TREATMENT OF HAIR
BRPI0914139A2 (en) Pediatric compositions for the treatment of multiple sclerosis